These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 30768766)

  • 1. Semaglutide as a promising antiobesity drug.
    Christou GA; Katsiki N; Blundell J; Fruhbeck G; Kiortsis DN
    Obes Rev; 2019 Jun; 20(6):805-815. PubMed ID: 30768766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wegovy (semaglutide): a new weight loss drug for chronic weight management.
    Singh G; Krauthamer M; Bjalme-Evans M
    J Investig Med; 2022 Jan; 70(1):5-13. PubMed ID: 34706925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of once-weekly semaglutide vs. once-daily liraglutide administered subcutaneously in patients with overweight and obesity: a decision analysis.
    Alshahawey M; Ghazy M; El Morshedy M; El Said NO
    Eur Rev Med Pharmacol Sci; 2024 May; 28(9):3365-3374. PubMed ID: 38766793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
    Rubino D; Abrahamsson N; Davies M; Hesse D; Greenway FL; Jensen C; Lingvay I; Mosenzon O; Rosenstock J; Rubio MA; Rudofsky G; Tadayon S; Wadden TA; Dicker D;
    JAMA; 2021 Apr; 325(14):1414-1425. PubMed ID: 33755728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profile of once-weekly injectable semaglutide for chronic weight management.
    Lau DCW; Batterham RL; le Roux CW
    Expert Rev Clin Pharmacol; 2022 Mar; 15(3):251-267. PubMed ID: 35466848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.
    Guo X; Zhou Z; Lyu X; Xu H; Zhu H; Pan H; Wang L; Yang H; Gong F
    Horm Metab Res; 2022 Jul; 54(7):458-471. PubMed ID: 35512849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semaglutide 2.4-mg injection as a novel approach for chronic weight management.
    Kyrillos J
    Am J Manag Care; 2022 Dec; 28(15 Suppl):S297-S306. PubMed ID: 36525677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].
    Scheen AJ
    Rev Med Liege; 2019 Sep; 74(9):488-494. PubMed ID: 31486321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semaglutide for Weight Loss: Was It Worth the Weight?
    Novograd J; Mullally J; Frishman WH
    Cardiol Rev; 2022 Nov-Dec 01; 30(6):324-329. PubMed ID: 36201244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Christensen RM; Juhl CR; Torekov SS
    Drug Saf; 2019 Aug; 42(8):957-971. PubMed ID: 30972641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
    Blundell J; Finlayson G; Axelsen M; Flint A; Gibbons C; Kvist T; Hjerpsted JB
    Diabetes Obes Metab; 2017 Sep; 19(9):1242-1251. PubMed ID: 28266779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
    Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
    Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical review of subcutaneous semaglutide for obesity.
    Phillips A; Clements JN
    J Clin Pharm Ther; 2022 Feb; 47(2):184-193. PubMed ID: 34964141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semaglutide (Ozempic) for weight loss.
    Med Lett Drugs Ther; 2021 Apr; 63(1621):53-54. PubMed ID: 33830968
    [No Abstract]   [Full Text] [Related]  

  • 18. [The glucagon-like peptide-1 receptor-agonist semaglutide].
    Boje AD; Juhl CR; Torekov SS; Madsbad S
    Ugeskr Laeger; 2019 Oct; 181(41):. PubMed ID: 31610830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semaglutide once-weekly: improved efficacy with a new safety warning.
    Coon SA; Crannage EF; Kerwin LC; Guyton JE
    Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1061-1072. PubMed ID: 30296182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Semaglutide and obesity: beyond the nutritional and lifestyle intervention?
    Basile L; Cannarella R; Iuliano S; Calogero AE; Condorelli RA; Greco EA; Aversa A; LA Vignera S
    Minerva Endocrinol (Torino); 2024 Jun; 49(2):182-195. PubMed ID: 39028209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.